Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

Recruiting Observational Study
glp1 Agonist Gene Expression Skin Laxity
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
30 – 65
Sex
Any
Study type
Observational
Participants needed
10 (estimated)
Sponsor
Cytrellis Biosystems, Inc. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight lo…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Male and female adult, between the ages of 30 and 65 2. Fitzpatrick Skin Type I-VI 3. Have moderate to severe wrinkles on the mid and lower face, according to Lemperle Wrinkle Severity Scale (LWSS), i.e. score 3, 4 or 5. 4. Have moderate to extreme abdominal laxity according …
Contacts

Karyn Siemasko, PhD

949-394-0585

ksiemasko@cytrellis.com

CONTACT

Delia Khayat, PharmD

305-484-4948

dkhayat@cytrellis.com

CONTACT